8 Results for "

Oxalate Oxidase

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "Oxalate Oxidase" in MCE Product Catalog:

Cat. No.: HY-E70385
CAS No.: 9031-79-2
Target:  

Endogenous Metabolite

Research Areas:  

Others

Oxalate Oxidase, or oxalate oxidase, catalyzes the oxidation of oxalic acid to hydrogen peroxide and carbon dioxide in the presence of oxygen. Oxalate Oxidase can be found in a variety of plants (such as barley) and microorganisms and can be used to treat wastewater and filtrates containing oxalic acid .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132588
CAS No.: 1834610-13-7
Synonyms: ALN-G01
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132613
CAS No.: 1834612-06-4
Purity:  99.21%
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
Cat. No.: HY-W088011B
CAS No.: 2836-32-0
Synonyms: Sodium hydroxyacetate, 98%
Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active, versatile organic salt . Sodium glycolate, 98% acts as an enzyme activity regulator that increases the activities of glycolate oxidase (GAO) and lactate dehydrogenase (LDH), while reducing the activity of glycolate dehydrogenase (GAD). Sodium glycolate, 98% induces oxalate biosynthesis and causes hyperoxaluria in rats. Sodium glycolate, 98% reduces urinary calcium excretion in male albino rats. Sodium glycolate, 98% can be used in studies related to calcium oxalate urolithiasis and hyperoxaluria .
loading...
    loading...
Cat. No.: HY-148610
CAS No.: 893739-96-3
Target:  

Others

Research Areas:  

Metabolic Disease

LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
Cat. No.: HY-W176012
CAS No.: 330977-65-6
Target:  

Others

Research Areas:  

Metabolic Disease

Glycolate oxidase-IN-1(compound 26), a salicylic acid derivative, is a glycolate oxidase (GO) inhibitor with an IC50 of 38.2 μM. Glycolate oxidase-IN-1 has the ability to reduce oxalate production in hyperoxalate hepatocytes and can be used in the study of primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
Cat. No.: HY-E70385A
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

Oxalate oxidase, B. subtilis (EC 1.2.3.4) is a redox enzyme that acts on the donor aldehyde or carbonyl group, using oxygen as the acceptor. Oxalate oxidase, B is involved in the metabolism of glyoxylate and dicarboxylic acids. Oxalate oxidase, B has two cofactors: FAD and manganese. Oxalate oxidase, B has three substrates: oxalic acid, O2, and H +, and two products: CO2 and H2O2.
loading...
    loading...
Cat. No.: HY-180992
Target:  

Lactate Dehydrogenase

Research Areas:  

Metabolic Disease

Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1 .
loading...
    loading...